The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Source: View publication →
In patients with generalized or unclassifiable epilepsy, valproate demonstrated superior efficacy regarding time to treatment failure and 12-month seizure remission compared to lamotrigine and topiramate, solidifying its role as the first-line treatment.
Key Findings
Study Design
Study Limitations
Clinical Significance
The findings support the continued use of valproate as the preferred first-line treatment for generalized and unclassifiable epilepsy syndromes due to its superior long-term efficacy and retention rates compared to lamotrigine and topiramate. Clinicians must weigh this efficacy against individual patient risks, particularly regarding reproductive health.
Historical Context
At the time of the study, valproate was the established standard for generalized epilepsy, while newer agents like lamotrigine and topiramate were gaining popularity. The SANAD trial (Arm B) was initiated to rigorously compare these drugs in a real-world clinical setting to provide empirical evidence for first-line treatment selection.
Guided Discussion
High-yield insights from every perspective
Given that the SANAD study focuses on generalized and unclassifiable epilepsy, what are the primary neurochemical mechanisms of action that differentiate sodium valproate from lamotrigine in its ability to treat multiple seizure types simultaneously?
Key Response
Sodium valproate is a broad-spectrum antiepileptic drug that acts via multiple mechanisms: it increases GABA levels by inhibiting its degradation, blocks voltage-gated sodium channels, and modulates T-type calcium channels. This multifaceted approach makes it effective against the various discharges seen in generalized epilepsies (such as 3Hz spike-and-wave). In contrast, lamotrigine primarily targets sodium channels, which, while effective for focal and tonic-clonic seizures, can occasionally exacerbate certain generalized symptoms like myoclonus.
The SANAD trial identified valproate as superior for generalized epilepsy, yet clinical practice often avoids it in females of childbearing age. Based on the study's primary outcomes, how should a clinician quantify the trade-off in 'time to treatment failure' when choosing lamotrigine over valproate in a 22-year-old female with idiopathic generalized epilepsy?
Key Response
While valproate showed superior time to treatment failure and 12-month remission in SANAD, the clinical decision for residents involves balancing this efficacy against valproate’s known teratogenicity and polycystic ovary syndrome risk. Lamotrigine has a lower risk of birth defects but a higher rate of treatment failure due to inferior seizure control in generalized syndromes. Residents must use shared decision-making to explain that choosing lamotrigine may prioritize safety for future pregnancies at the potential cost of delayed seizure control.
In the SANAD study, 'unclassifiable' epilepsy was a significant category. How do the trial's findings influence the management of a patient whose EEG is non-diagnostic but whose clinical history suggests a generalized onset, and why might topiramate's performance in this trial be considered a 'tolerability failure' rather than an 'efficacy failure'?
Key Response
SANAD demonstrated that valproate is the drug of choice for 'unclassifiable' cases where a generalized component is suspected. Regarding topiramate, the study noted a high rate of treatment withdrawal; fellows should recognize that while topiramate is potent, its clinical utility is limited by cognitive side effects (e.g., word-finding difficulties) and psychiatric symptoms, leading to 'failure' in the trial's composite endpoint of drug retention even if seizures were suppressed.
As we integrate the long-term findings of the SANAD I trial into modern practice, how does the emergence of newer broad-spectrum agents like levetiracetam and brivaracetam challenge valproate's status as the 'gold standard' for generalized epilepsy, and what teaching points should we emphasize regarding the 'effectiveness' vs 'efficacy' gap?
Key Response
SANAD I established valproate as the gold standard for effectiveness (retention) and efficacy (seizure freedom). While newer drugs offer better safety profiles and fewer drug-drug interactions, recent head-to-head evidence (like SANAD II) still struggles to demonstrate superior seizure control compared to valproate. The teaching point is that 'newer' is not synonymous with 'more effective' for seizure remission, and valproate remains the efficacy benchmark against which all newer generalized epilepsy treatments must be measured.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SANAD trial employed a pragmatic, unblinded design. Critically evaluate how the lack of blinding might have introduced performance bias in the assessment of 'time to treatment failure,' particularly concerning the clinician's threshold for switching medications in the valproate arm versus the topiramate arm.
Key Response
In an unblinded trial, clinicians' prior beliefs about a drug's 'classic' side effects or 'fabled' efficacy can influence their decision to maintain a patient on a drug despite minor adverse events or breakthrough seizures. If clinicians perceived valproate as the 'true' first-line agent, they might have been more likely to encourage patients to tolerate side effects, whereas they might have been quicker to discontinue topiramate due to its known reputation for cognitive impairment, thus biasing the 'time to treatment failure' endpoint.
What are the specific threats to internal validity posed by the heterogeneous inclusion of 'generalized' and 'unclassifiable' epilepsy syndromes in a single trial arm, and would a more stringent exclusion of 'unclassifiable' cases have altered the editorial significance of the SANAD study?
Key Response
A tough reviewer would flag that 'unclassifiable' is a heterogeneous group that might include unrecognized focal epilepsies. If a significant portion were actually focal, it could dilute the observed efficacy of valproate or unfairly disadvantage lamotrigine (which is highly effective for focal seizures). However, from an editorial standpoint, including 'unclassifiable' cases increases the trial's pragmatic value and external validity, as it reflects the real-world diagnostic uncertainty faced by neurologists at the point of initial prescription.
Considering the SANAD I results alongside the 2018 EMA and MHRA restrictions on valproate, how should the ILAE or NICE guidelines reconcile the 'Level A' evidence for valproate's superior efficacy with the mandatory 'Pregnancy Prevention Programme' requirements?
Key Response
Guideline committees must now provide stratified recommendations. For males and children, SANAD I provides the highest level of evidence for valproate as first-line. For females of childbearing potential, guidelines must prioritize safer alternatives (like lamotrigine or levetiracetam) as first-line despite the SANAD evidence of lower efficacy, reserving valproate only for cases where other treatments have failed and the stringent criteria of the Pregnancy Prevention Programme are met. This reflects a shift from an 'efficacy-first' guideline to a 'safety-first' regulatory landscape.
Clinical Landscape
Noteworthy Related Trials
VA Cooperative Study 118
Tested
Carbamazepine, Phenytoin, Phenobarbital, or Primidone
Population
Adults with newly diagnosed partial or generalized tonic-clonic seizures
Comparator
Other antiepileptic drug monotherapy
Endpoint
Time to treatment failure or seizure recurrence
SANAD II Trial
Tested
Levetiracetam
Population
Patients with newly diagnosed focal epilepsy
Comparator
Zonisamide
Endpoint
Time to treatment failure due to inadequate seizure control or unacceptable adverse events
Standard and New Antiepileptic Drugs (SANAD) II
Tested
Valproate
Population
Children and adults with newly diagnosed generalized or unclassifiable epilepsy
Comparator
Levetiracetam
Endpoint
Time to treatment failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis